Amrutanjan Health Care Limited (AMRUTANJAN.BO)
INR 749.5
(-0.43%)
INR 749.5
(-0.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 457.54 Million INR | 5.76% |
| 2022 | 432.61 Million INR | -46.48% |
| 2021 | 808.36 Million INR | 11.66% |
| 2020 | 723.98 Million INR | 165.22% |
| 2019 | 272.97 Million INR | -6.41% |
| 2018 | 291.67 Million INR | 12.16% |
| 2017 | 260.04 Million INR | -21.52% |
| 2016 | 331.34 Million INR | -4.13% |
| 2015 | 345.61 Million INR | 43.12% |
| 2014 | 241.49 Million INR | 24.61% |
| 2013 | 193.8 Million INR | 25.24% |
| 2012 | 154.74 Million INR | -4.01% |
| 2011 | 161.2 Million INR | 1.09% |
| 2010 | 159.45 Million INR | -5.59% |
| 2009 | 168.89 Million INR | -6.54% |
| 2008 | 180.7 Million INR | 90.56% |
| 2007 | 94.82 Million INR | -36.26% |
| 2006 | 148.76 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 19.61 Million INR | -86.66% |
| 2023 Q3 | 199.96 Million INR | 278.18% |
| 2023 Q1 | 57.67 Million INR | -50.58% |
| 2023 FY | 457.54 Million INR | 5.76% |
| 2023 Q2 | 52.87 Million INR | -8.32% |
| 2023 Q4 | 147.02 Million INR | -26.47% |
| 2022 Q4 | 116.68 Million INR | 7.63% |
| 2022 Q1 | 22.62 Million INR | -85.08% |
| 2022 Q2 | 144.07 Million INR | 536.83% |
| 2022 FY | 432.61 Million INR | -46.48% |
| 2022 Q3 | 108.41 Million INR | -24.75% |
| 2021 Q4 | 151.59 Million INR | -38.74% |
| 2021 FY | 808.36 Million INR | 11.66% |
| 2021 Q1 | 136.32 Million INR | 19.61% |
| 2021 Q2 | 221.4 Million INR | 62.41% |
| 2021 Q3 | 247.46 Million INR | 11.77% |
| 2020 Q1 | 87.06 Million INR | -18.72% |
| 2020 Q4 | 113.97 Million INR | -59.56% |
| 2020 Q3 | 281.86 Million INR | -10.33% |
| 2020 Q2 | 314.33 Million INR | 261.06% |
| 2020 FY | 723.98 Million INR | 165.22% |
| 2019 Q2 | 121.73 Million INR | 1525.91% |
| 2019 Q4 | 107.1 Million INR | -15.3% |
| 2019 Q3 | 126.45 Million INR | 3.88% |
| 2019 Q1 | -8.53 Million INR | -104.28% |
| 2019 FY | 272.97 Million INR | -6.41% |
| 2018 Q1 | -20.26 Million INR | -119.44% |
| 2018 FY | 291.67 Million INR | 12.16% |
| 2018 Q4 | 199.41 Million INR | 163.83% |
| 2018 Q3 | 75.58 Million INR | -20.37% |
| 2018 Q2 | 94.92 Million INR | 568.39% |
| 2017 Q2 | 142.69 Million INR | 1062.22% |
| 2017 FY | 260.04 Million INR | -21.52% |
| 2017 Q3 | 79.89 Million INR | -44.01% |
| 2017 Q4 | 104.26 Million INR | 30.5% |
| 2017 Q1 | -14.83 Million INR | -119.93% |
| 2016 Q3 | 84.52 Million INR | -24.36% |
| 2016 Q2 | 111.74 Million INR | 0.0% |
| 2016 FY | 331.34 Million INR | -4.13% |
| 2016 Q4 | 74.42 Million INR | -11.95% |
| 2015 FY | 345.61 Million INR | 43.12% |
| 2014 FY | 241.49 Million INR | 24.61% |
| 2013 FY | 193.8 Million INR | 25.24% |
| 2012 Q2 | 50.83 Million INR | 667.0% |
| 2012 Q3 | 54.78 Million INR | 7.76% |
| 2012 Q4 | 67.28 Million INR | 22.83% |
| 2012 FY | 154.74 Million INR | -4.01% |
| 2012 Q1 | 6.62 Million INR | 0.0% |
| 2011 FY | 161.2 Million INR | 1.09% |
| 2010 FY | 159.45 Million INR | -5.59% |
| 2009 FY | 168.89 Million INR | -6.54% |
| 2008 FY | 180.7 Million INR | 90.56% |
| 2007 FY | 94.82 Million INR | -36.26% |
| 2006 FY | 148.76 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Ajanta Pharma Limited | 19.67 Billion INR | 97.675% |
| Sigachi Industries Limited | 1.47 Billion INR | 68.957% |
| Bal Pharma Limited | 233.9 Million INR | -95.608% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 89.65% |
| Medico Remedies Limited | 100.3 Million INR | -356.175% |
| Lasa Supergenerics Limited | -458 Million INR | 199.899% |
| Venus Remedies Limited | 534.65 Million INR | 14.422% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 111.119% |
| Alpa Laboratories Limited | 184.49 Million INR | -147.995% |
| Nectar Lifesciences Limited | 923.8 Million INR | 50.472% |
| Shilpa Medicare Limited | 1.36 Billion INR | 66.511% |
| Aarti Drugs Limited | 7.14 Billion INR | 93.6% |
| Lupin Limited | 28.04 Billion INR | 98.369% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 98.916% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 98.939% |
| Windlas Biotech Limited | 1.29 Billion INR | 64.774% |
| Suven Life Sciences Limited | -1.22 Billion INR | 137.325% |
| Eris Lifesciences Limited | 5.18 Billion INR | 91.17% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 96.797% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 111.875% |
| Ipca Laboratories Limited | 7.98 Billion INR | 94.267% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 62.832% |
| Achyut Healthcare Limited | 4.43 Million INR | -10209.689% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.561% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| RPG Life Sciences Limited | 2.29 Billion INR | 80.04% |
| Mankind Pharma Limited | 21.51 Billion INR | 97.874% |
| Laurus Labs Limited | 3.94 Billion INR | 88.413% |
| Piramal Pharma Limited | 4.55 Billion INR | 89.959% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -83.568% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 98.194% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 92.054% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 92.963% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 26.968% |
| Wanbury Limited | 569.71 Million INR | 19.689% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 90.07% |
| Wockhardt Limited | -670 Million INR | 168.29% |
| Themis Medicare Limited | 392.58 Million INR | -16.545% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 9.955% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 91.182% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 94.904% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.324% |
| Divi's Laboratories Limited | 33.08 Billion INR | 98.617% |
| NATCO Pharma Limited | 25.96 Billion INR | 98.238% |
| Gufic Biosciences Limited | 1.32 Billion INR | 65.596% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 71.346% |
| Ind-Swift Limited | 1.22 Billion INR | 62.679% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 83.577% |
| FDC Limited | 2.98 Billion INR | 84.678% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 401.101% |
| Granules India Limited | 6.81 Billion INR | 93.288% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Alkem Laboratories Limited | 19.46 Billion INR | 97.649% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 73.36% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -4945.31% |
| Brooks Laboratories Limited | 14.44 Million INR | -3068.587% |
| Megasoft Limited | -121.1 Million INR | 477.811% |
| ZIM Laboratories Limited | 253.82 Million INR | -80.257% |
| Strides Pharma Science Limited | 5.22 Billion INR | 91.245% |
| Neuland Laboratories Limited | 5.31 Billion INR | 91.396% |
| Morepen Laboratories Limited | 4.17 Billion INR | 89.038% |
| Hikal Limited | 32.11 Million INR | -1324.927% |
| Indoco Remedies Limited | 1.29 Billion INR | 64.601% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 85.373% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -119.92% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -1566.341% |
| Hester Biosciences Limited | 364.81 Million INR | -25.42% |